Catalent Announces Major China Expansion with Two New Facilities for Softgel Technologies and Clinical Supply Solutions Businesses
SOMERSET, N.J.--(BUSINESS WIRE)--
Catalent Pharma Solutions, the global leader in drug development
solutions and advanced delivery technologies for pharmaceutical,
biologic and consumer health products, today announced two joint
ventures in China for its Softgel Technologies and Clinical Supply
Solutions businesses. Catalent continues to expand its global leadership
by providing access to drug delivery and clinical trial capabilities for
customers in Asia Pacific. The company intends to make additional
investments in these two facilities over the next several years to
broaden its offerings in the Chinese market.
First, Catalent has agreed to acquire, pending regulatory approvals, a
majority share in Haining-based, privately held . The business produces nutritional
softgel products for Chinese and Asia Pacific markets, and employs 120
staff. Catalent intends to work with regulators for future expansion
into OTC and prescription softgel manufacturing in China.
In the second announcement, Catalent and ShangPharma Corporation, a
leading China-based pharmaceutical and biotechnology research and
development outsourcing company, have formed a joint-venture called
Catalent (Shanghai) Clinical Trial Supplies Co., Ltd. A new 31,000 sq ft
facility in Shanghai, which is currently under construction, will be the
first in China to provide end-to-end solutions for clinical trial
supplies, including comparator sourcing, primary and secondary packaging
and labeling, and storage and distribution.
Commenting on both investments, Catalents President & CEO, John
Chiminski said, .
Hui, founder and CEO of ShangPharma.
The Chairman & CEO of Zhejiang commented
No other terms of the transactions have been disclosed.
Catalent Pharma Solutions is the global leader in development solutions
and advanced drug delivery technologies, providing world-wide clinical
and commercial supply capabilities for drugs, biologics and consumer
health products. With over 75 years serving the industry, Catalent has
proven expertise in bringing more customer products to market faster,
enhancing product performance and ensuring reliable product supply.
Catalent employs approximately 9,000 people, including over 1,000
scientists, at nearly 30 facilities across 5 continents and generates
more than $1.7 billion in annual revenue. Catalent is headquartered in
Somerset, N.J. For more information, visit www.catalent.com.
ShangPharma Corporation is a leading China-based contract research
organization providing high-quality and cost-effective services for the
pharmaceutical and biotechnology industry. It offers a broad range of
high-quality, integrated services across the drug discovery and
development process to help international and Chinese pharmaceutical and
biotechnology companies discover and develop novel drug candidates
efficiently. ShangPharma's services consist of discovery chemistry,
discovery biology and preclinical development, pharmaceutical
development and biologics services. For more information, please visit www.shangpharma.com.
Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd., located in Haining,
Zhejiang Province, China, is specializing in producing nutritional
softgel products. The company has been serving customers in China and
Asia Pacific region since 2007.
Catalent Global:Elliott Berger, +firstname.lastname@example.orgCatalent
Europe:Chris Halling, +44 (0) 7580 041073Chris.email@example.comShangPharma
China:Josh Gartner, +86 (10) 5960 firstname.lastname@example.org
Source: Catalent Pharma Solutions